July/August 2021

NEWS & COLUMNS

6-7 NEWS
GSK aims for £33bn in sales by 2031; CHMP recommends eight new medicines for EU approval

8 NEWS
Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval; Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab

9 CORONAVIRUS NEWS
Vaccine makers test jabs against Delta variant

10-11 CORONAVIRUS NEWS
Court rules on AZ and EU's vaccine dispute; US announces $3bn funding boost for antiviral COVID-19 treatments

12 DARWIN'S MEDICINE
H is for hard – Turbocharging innovation is hard, especially in healthcare

13 POLICY AND PUBLIC HEALTH
Good things come to those who wait – except during a global pandemic

14 TRUST ME, I'M YOUR CEO
How can pharma maintain and enhance its own reputation by fulfilling the new expectations of it as a business?

15 PHARMA MARKETERS' BLOG
How to get the best out of your agency partners (and how not to!)

26 RESEARCH NEWS
The UK unveils its new ten-year Life Sciences Vision to support the life sciences sector

FEATURES

16-17 SILENCE THERAPEUTICS
Mark Rothera and Giles Campion discuss the company’s clinical programme, their focus on areas of high unmet need and the promising potential of precision medicines

18-19 GAIN THERAPEUTICS
EXPANDS INTO ONCOLOGY
Unlocking new treatments for difficult-to-treat disorders with a drug discovery platform that targets allosteric binding sites

20-21 A GLIMMER OF HOPE FOR
ALZHEIMER'S, BUT AT WHAT COST?
EU payers react after the shock of the FDA's early June approval of Biogen’s Aduhelm for the treatment
of Alzheimer’s disease

22-23 THE PATIENT VOICE IN
CLINICAL TRIAL DEVELOPMENT
Patients need to understand what they are signing up to and what inclusion in a clinical trial could mean to them, and listening to the patient voice increases engagement and involvement